Takeda allies with Resolve to develop autoimmune disease drugs

03/1/2013 | Genetic Engineering & Biotechnology News

Takeda Pharmaceutical and Resolve Therapeutics agreed to collaborate on treatments for systemic lupus erythematosus and other autoimmune disorders, with an initial focus on Resolve's nuclease Fc fusion protein RSLV-132. The deal gives Takeda an exclusive option to license all Resolve compounds following a study on RSLV-132. Resolve will get $8 million for clinical development, a potential option exercise payment and as much as $247 million in milestone fees plus sales royalties.

View Full Article in:

Genetic Engineering & Biotechnology News

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Corporate Life Sciences Lawyer (3-5 years exp)
Ropes & Gray LLP
Boston, MA; San Francisco, CA; Silicon Valley, CA, MA
Director of Accreditation
Meridian Health Plan
Detroit, MI
Health Services Researcher
AARP
Washington, DC
Chief Executive Officer
Center for Improving Value in Healthcare
Denver, CO
Senior director risk adjustor and coding doc
Novant Health
Charlotte, NC